← All trials
NCT05221021
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Dec 30, 2023
- Completion date
- Jan 30, 2024
- First posted
- Feb 2, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- United States ArmyLead sponsor
- United States ArmyReponsible party - principal investigator
- United States ArmySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.